On April 26, 2019 Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, reported that it will report its first quarter 2019 financial and operating results after the close of U.S. financial markets on Thursday, May 2, 2019 (Press release, Alder Biopharmaceuticals, APR 26, 2019, https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-host-conference-call-discuss-first-0 [SID1234535432]). Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers and providing conference ID number 8162289. The webcast can be accessed from the Events & Presentations page of the Investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for at least 30 days.

On April 26, 2019 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, reported that the company will release its first quarter 2019 financial results after the market closes on Tuesday, May 7, 2019 (Press release, CohBar, APR 26, 2019, View Source [SID1234535431]). Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the Conference Call and Slide Presentation:

Date: May 7, 2019
Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference Audio

Dial-in U.S. and Canada: (800) 289-0438
Dial-in International: (323) 794-2423
Conference ID No.: 1071020
Slide Presentation

Go to www.webex.com, click on the ‘Join’ button and enter meeting number 924 256 010 and Password CWBR, or
Go to www.cohbar.com and click on Q1 2019 Shareholder Presentation at top of homepage.
We kindly request that you please call into the conference audio approximately 10 minutes prior to the start time so that we can begin promptly.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on May 7, 2019, through 11:59 p.m. Eastern Time on May 28, 2019. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 1071020. The audio replay along with the slide presentation will also be available on the homepage at www.cohbar.com from May 7, 2019 through May 28, 2019.

On April 26, 2019 PharmaMar Group (MSE: PHM) reported total sales of €18.4 million in the first three months of 2019, compared to €19.7 million in the same period of 2018 (Press release, PharmaMar, APR 26, 2019, View Source [SID1234535430]). Sales of Yondelis accounted for €17.1 million, compared to €18.4 million in March 2018. As in previous quarters, price erosion was one of the main factors behind the difference in Yondelis sales figures between quarters.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the first three months of 2019, royalty income of €0.9 million was recorded, compared to €1.4 million during the first three months of the previous year. In relation to license revenues, no license revenues were recorded in the first quarter of 2019, which explains the difference in total revenues in this period (€19.4 million, compared to €27.8 million in 2018). After the closing date, a license agreement has been signed with Luye Pharma Group Ltd. for the marketing of Zepsyre (lurbinectedin) in China, with an initial payment of US$5 million as part of the agreement, which will be registered in the second quarter of this year.

Sales in the consumer chemicals sector, which grew by 16.6% in the first quarter, are not included in the Group’s total revenues as the companies forming part of the sector were classified as available for sale/interrupted operations, both in March 2019 and in the same period in 2018.

As a result, at the end of the first quarter of 2019, the group’s EBITDA was €-7.1 million compared to €-2.6 million in March 2018.

At March 31, 2018, the Group’s profit from continuing operations was €-10.4 million compared to €-2.5 million in the first quarter of 2018.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction

On April 26, 2019 BioInvent International AB (OMXS: BINV) reported that it has received a €0.75 million milestone payment under its collaboration with Mitsubishi Tanabe Pharma Corporation in connection with enrollment of the first patient in a Phase II clinical trial of an antibody identified from BioInvent’s proprietary n-CoDeR antibody library (Press release, BioInvent, APR 26, 2019, View Source [SID1234535427]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The license agreement with Mitsubishi Tanabe Pharma covers development of antibodies from the n-CoDeR antibody library.

"It is very satisfying to see that our high quality recombinant human antibody library n-CoDeR is not only delivering candidates for BioInvent’s proprietary programs, but is also proving beneficial for our partners in developing their own pipeline," said BioInvent CEO Martin Welschof.

Under the terms of the agreement, payments are due to BioInvent when certain clinical milestones are achieved and royalty payments are due when a product is sold on the market. Enrollment of a first patient in a Phase II clinical trial is a milestone that triggers a payment to BioInvent.

On April 26, 2019 PharmaMar (MSE:PHM) has reported an agreement with Hong Kong listed Luye Pharma Group Ltd. (HKG:2186) to develop and commercialize the marine-inspired anti-tumor compound, lurbinectedin (Zepsyre) in Small Cell Lung Cancer (SCLC), and potentially in other indications in China, Hong Kong and Macao (Press release, PharmaMar, APR 26, 2019, View Source [SID1234535426]).

Under the terms of this agreement, PharmaMar will receive an up-front payment of US $5 million followed by additional payments for regulatory and sales milestones, as well as double-digit royalties. This income may be increased if other therapeutic indications are approved.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Luye Pharma will commit to develop lurbinectedin in SCLC in China, while PharmaMar will retain exclusive production rights for the compound.

José María Fernández Sousa-Faro, PhD, President of PharmaMar, commented, "PharmaMar is delighted to team-up with Luye Pharma Group Ltd. for China, a leader in the above mentioned space with an outstanding track record in Oncology, that has successfully brought innovative cancer medicines to Chinese patients."

Rongbing Yang, President of Luye Pharma Group Ltd., said about this new licensing deal: "This agreement with PharmaMar enables us to address the treatment of this type of disease in China, which is much more widespread than in the US and Europe.Oncology is one of the core therapeutic areas for Luye Pharma’s long-term development. We will continue to increase investment to further enrich our oncology pipelines and enhance our competitiveness in this field of treatment, through external partnerships with more innovative companies such as PharmaMar and also through our in-house R&D innovation".

2 According to data from the World Health Organization (WHO), China has the highest number of cancer cases in the world, due to population ageing, tobacco and pollution. China is also the country with the highest mortality rate in Asia for lung cancer. This type of tumor affects a larger number of people than in the U.S., Europe and Japan combined. The WHO estimates that by 2020, 800,000 new cases of lung cancer will be diagnosed and will cause nearly 700,000 deaths. It is estimated that SCLC represents approximately 18% of all lung cancers in China.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.